One-pot N-glycosylation remodeling of IgG with non-natural sialylglycopeptides enables glycosite-specific and dual-payload antibody-drug conjugates.

Chemoenzymatic transglycosylation catalyzed by endo-S mutants is a powerful tool for in vitro glycoengineering of therapeutic antibodies. In this paper, we report a one-pot chemoenzymatic synthesis of glycoengineered Herceptin using an egg-yolk sialylglycopeptide (SGP) substrate. Combining this one-pot strategy with novel non-natural SGP derivatives carrying azido or alkyne tags, glycosite-specific conjugation was enabled for the development of new antibody-drug conjugates (ADCs). The site-specific ADCs and semi-site-specific dual-drug ADCs were successfully achieved and characterized with SDS-PAGE, intact antibody or ADC mass spectrometry analysis, and PNGase-F digestion analysis. Cancer cell cytotoxicity assay revealed that small-molecule drug release of these ADCs relied on the cleavable Val-Cit linker fragment embedded in the structure. These results represent a new approach for glycosite-specific and dual-drug ADC design and rapid synthesis, and also provide the structural requirement for their biologic activities.

[1]  Xiuru Li,et al.  Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions. , 2014, Angewandte Chemie.

[2]  M. Noguchi,et al.  Efficient synthesis of sugar oxazolines from unprotected N-acetyl-2-amino sugars by using chloroformamidinium reagent in water. , 2009, The Journal of organic chemistry.

[3]  Jason S. Lewis,et al.  Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. , 2013, Bioconjugate chemistry.

[4]  Robert M. Anthony,et al.  Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc , 2008, Science.

[5]  Bing Li,et al.  Highly efficient endoglycosidase-catalyzed synthesis of glycopeptides using oligosaccharide oxazolines as donor substrates. , 2005, Journal of the American Chemical Society.

[6]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[7]  J. Leusen,et al.  Fc receptor inside‐out signaling and possible impact on antibody therapy , 2015, Immunological reviews.

[8]  Yang Feng,et al.  Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar , 2014, mAbs.

[9]  Hong Liu,et al.  A simplified procedure for gram-scale production of sialylglycopeptide (SGP) from egg yolks and subsequent semi-synthesis of Man3GlcNAc oxazoline. , 2014, Carbohydrate research.

[10]  Naoko Yamane-Ohnuki,et al.  Production of therapeutic antibodies with controlled fucosylation , 2009, mAbs.

[11]  Armin Ruf,et al.  Unique carbohydrate–carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose , 2011, Proceedings of the National Academy of Sciences.

[12]  J. Ravetch,et al.  Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions , 2015, Cancer Immunology Research.

[13]  H. Kumagai,et al.  Novel specificities of Mucor hiemalis endo-beta-N-acetylglucosaminidase acting complex asparagine-linked oligosaccharides. , 1994, Bioscience, biotechnology, and biochemistry.

[14]  Qun Zhou,et al.  Advances in the Development of Site-Specific Antibody-Drug Conjugation. , 2015, Anti-cancer agents in medicinal chemistry.

[15]  C. J. Murray,et al.  Production of site-specific antibody-drug conjugates using optimized non-natural amino acids in a cell-free expression system. , 2014, Bioconjugate chemistry.

[16]  I. Sassoon,et al.  Antibody-drug conjugate (ADC) clinical pipeline: a review. , 2013, Methods in molecular biology.

[17]  L. Juneja,et al.  Occurence of a sialylglycopeptide and free sialylglycans in hen's egg yolk. , 1997, Biochimica et biophysica acta.

[18]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[19]  J. Briggs,et al.  Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. , 2001, Biochemistry.

[20]  F. Loganzo,et al.  Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates. , 2016, Bioconjugate chemistry.

[21]  D. Baeten,et al.  Control of Cytokine Production by Human Fc Gamma Receptors: Implications for Pathogen Defense and Autoimmunity , 2015, Front. Immunol..

[22]  Bing Li,et al.  Chemoenzymatic synthesis of HIV-1 V3 glycopeptides carrying two N-glycans and effects of glycosylation on the peptide domain. , 2005, The Journal of organic chemistry.

[23]  Increasing the efficacy of bioorthogonal click reactions for bioconjugation: a comparative study. , 2011, Angewandte Chemie.

[24]  Peter G Schultz,et al.  Synthesis of site-specific antibody-drug conjugates using unnatural amino acids , 2012, Proceedings of the National Academy of Sciences.

[25]  Bing Li,et al.  A highly efficient chemoenzymatic approach toward glycoprotein synthesis. , 2006, Organic letters.

[26]  Bin Liu,et al.  Methods for site-specific drug conjugation to antibodies , 2013, mAbs.

[27]  Alain Beck,et al.  GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins , 2010, Expert opinion on drug discovery.

[28]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[29]  Lai-Xi Wang,et al.  Arthrobacter Endo‐β‐N‐Acetylglucosaminidase Shows Transglycosylation Activity on Complex‐Type N‐Glycan Oxazolines: One‐Pot Conversion of Ribonuclease B to Sialylated Ribonuclease C , 2010, Chembiochem : a European journal of chemical biology.

[30]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[31]  B. Ramakrishnan,et al.  Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection. , 2009, Bioconjugate chemistry.

[32]  Xiuling Li,et al.  Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues. , 2015, Bioconjugate chemistry.

[33]  S. Salemi,et al.  The Expanding Role of Therapeutic Antibodies , 2015, International reviews of immunology.

[34]  Liming Liu,et al.  Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. , 2015, Journal of pharmaceutical sciences.

[35]  F. Nimmerjahn,et al.  The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo , 2011, Current opinion in organ transplantation.

[36]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[37]  D. Szymkowski,et al.  Harnessing Fc receptor biology in the design of therapeutic antibodies. , 2016, Current opinion in immunology.

[38]  Lai-Xi Wang,et al.  Expeditious chemoenzymatic synthesis of homogeneous N-glycoproteins carrying defined oligosaccharide ligands. , 2008, Journal of the American Chemical Society.

[39]  F. V. van Delft,et al.  Chemoenzymatic Conjugation of Toxic Payloads to the Globally Conserved N-Glycan of Native mAbs Provides Homogeneous and Highly Efficacious Antibody-Drug Conjugates. , 2015, Bioconjugate chemistry.

[40]  Johnny Gonzales,et al.  In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase. , 2005, Biotechnology and bioengineering.

[41]  Peter G Schultz,et al.  A general approach to site-specific antibody drug conjugates , 2014, Proceedings of the National Academy of Sciences.

[42]  P. Carter,et al.  Antibody-Drug Conjugates for Cancer Therapy , 2008, Cancer journal.

[43]  David Ouellette,et al.  Increased serum clearance of oligomannose species present on a human IgG1 molecule , 2012, mAbs.

[44]  G. Weiner.  Building better monoclonal antibody-based therapeutics , 2015, Nature Reviews Cancer.

[45]  B. G. Davis,et al.  An endoglycosidase with alternative glycan specificity allows broadened glycoprotein remodelling. , 2012, Journal of the American Chemical Society.

[46]  Wei Huang,et al.  Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions. , 2012, Journal of the American Chemical Society.

[47]  Lai-Xi Wang,et al.  Glycosynthases enable a highly efficient chemoenzymatic synthesis of N-glycoproteins carrying intact natural N-glycans. , 2009, Journal of the American Chemical Society.

[48]  J. Ravetch,et al.  Type I and type II Fc receptors regulate innate and adaptive immunity , 2014, Nature Immunology.

[49]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[50]  J. Ravetch,et al.  Identification of a receptor required for the anti-inflammatory activity of IVIG , 2008, Proceedings of the National Academy of Sciences.

[51]  P. V. van Berkel,et al.  Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose , 2011, Biotechnology and bioengineering.

[52]  B. Tomczuk,et al.  Current ADC Linker Chemistry , 2015, Pharmaceutical Research.

[53]  P. Bondarenko,et al.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.

[54]  M. Wolfert,et al.  Visualizing metabolically labeled glycoconjugates of living cells by copper-free and fast huisgen cycloadditions. , 2008, Angewandte Chemie.

[55]  Keith Brew,et al.  Screening a limited structure-based library identifies UDP-GalNAc-specific mutants of alpha-1,3-galactosyltransferase. , 2008, Glycobiology.

[56]  Youwei Jiang,et al.  Optimization of humanized IgGs in glycoengineered Pichia pastoris , 2006, Nature Biotechnology.

[57]  J. Golay,et al.  Lepidopteran cells, an alternative for the production of recombinant antibodies? , 2012, mAbs.

[58]  Jennifer A. Prescher,et al.  A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. , 2004, Journal of the American Chemical Society.

[59]  P. Drake,et al.  An emerging playbook for antibody-drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety. , 2015, Current opinion in chemical biology.

[60]  Gonçalo J. L. Bernardes,et al.  Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry , 2016, Chemical science.

[61]  Chi‐Huey Wong,et al.  A common glycan structure on immunoglobulin G for enhancement of effector functions , 2015, Proceedings of the National Academy of Sciences.

[62]  Carolyn R. Bertozzi,et al.  Copper-free click chemistry for dynamic in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[63]  J. Moir,et al.  Endohexosaminidase-catalysed glycosylation with oxazoline donors: fine tuning of catalytic efficiency and reversibility. , 2008, Chemistry.

[64]  T. Claridge,et al.  Synthesis of N-glycan oxazolines: donors for endohexosaminidase catalysed glycosylation. , 2006, Carbohydrate research.

[65]  S. Mohammed,et al.  Optimal Synthetic Glycosylation of a Therapeutic Antibody , 2016, Angewandte Chemie.

[66]  Saurabh Aggarwal,et al.  What's fueling the biotech engine--2010 to 2011. , 2011, Nature biotechnology.

[67]  S. Kaufmann,et al.  Host-directed therapies for infectious diseases: current status, recent progress, and future prospects , 2016, The Lancet Infectious Diseases.

[68]  J. Ravetch,et al.  Novel roles for the IgG Fc glycan , 2012, Annals of the New York Academy of Sciences.

[69]  Bing Li,et al.  Mutants of Mucor hiemalis Endo-β-N-acetylglucosaminidase Show Enhanced Transglycosylation and Glycosynthase-like Activities* , 2008, Journal of Biological Chemistry.

[70]  Lai-Xi Wang,et al.  Introducing N-glycans into natural products through a chemoenzymatic approach. , 2008, Carbohydrate research.

[71]  Kazuhiro Masuda,et al.  One-Step Conjugation Method for Site-Specific Antibody-Drug Conjugates through Reactive Cysteine-Engineered Antibodies. , 2016, Bioconjugate chemistry.